Name (Synonyms) | Correlation | |
---|---|---|
drug283 | Canakinumab Injection 300mg Wiki | 1.00 |
drug618 | Hydroxychloroquine Sulfate Loading Dose Wiki | 0.71 |
drug619 | Hydroxychloroquine Sulfate Regular dose Wiki | 0.71 |
drug308 | Chloroquine Wiki | 0.35 |
drug1042 | Placebos Wiki | 0.26 |
drug1016 | Placebo Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D058070 | Asymptomatic Diseases NIH | 0.71 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.
Description: Number of days
Measure: Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first. Time: Up to day 14Description: Number of days
Measure: Mortality at day 28 Time: Up to day 28